

Karger Continuing Education Series

Editor:
Gert Lubec, Vienna



Non- Invasive Diagnosis of Kidney Disease

142 figures, 1 colour plate, and 44 tables, 1983



KARGER

Basel München Paris London New York Tokyo Sydney

Karger Continuing Education Series

Editor:
Gert Lubec, Vienna



Non- Invasive Diagnosis of Kidney Disease

142 figures, 1 colour plate, and 44 tables, 1983



KARGER

Basel München Paris London New York Tokyo Sydney

Karger Continuing Education Series, Vol. 3

Topics covered in the Karger Continuing Education Series are selected to help improve clinical skills and introduce the reader to health-related areas undergoing exceptional growth. Produced as compact instructive texts, volumes set forth information which serves to heighten the general awareness and command of current medical procedures and practice. The concise textbook format enhances the value of these books as convenient teaching and training tools for medical scientists, medical clinicians, and health professionals.

National Library of Medicine, Cataloging in Publication

Non-invasive diagnosis of kidney disease

Editor, Gert Lubec. Basel, New York: Karger, 1983

(Karger continuing education series; v. 3)

I. Kidney disease—diagnosis. I. Lubec, Gert. II. Series

WJ 302 N812

ISBN 3-8055-3051-X

Drug Dosage

The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Copyright 1983 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)

Printed in Switzerland by Graphische Anstalt Schuler AG, Biel

ISBN 3-8055-3051-X



Preface

What does non-invasive mean? Non-invasive means that diagnosis should be made without pain or harm to the patient, or, at least, with a minimum of pain or harm.

Why take this attitude to pain? Whether pain is to be looked upon as an instrument of divine punishment or not, I do not think that suffering is 'a sign of grace, not to be evaded but sought' (*Sigerist, Medicine*). A leading theologian permits alcoholic intoxication '...to cure typhus, snake bites, and to relieve great pain' (*Genicot, Theologiae moralis institutiones*), which should also be the major task of modern medical treatment.

This book, which reports non-invasive methods to the nephrologist for the benefit of his patients, presents a small contribution to humanity in medicine.

Vienna, January 1983

Gert Lubec

List of Contributors

- Beck, Peter R., PhD, MB, ChB, Department of Clinical Biochemistry, Rotherham District General Hospital, Rotherham (England)
- Carty, Helen, MB, FRCPI, FRCR, Alder Hey Children's Hospital, Liverpool (England)
- Clark, P.M.S., PhD, Department of Clinical Chemistry, Wolfson Research Laboratories, Queen Elizabeth Medical Centre, Birmingham (England)
- Ellis, Demetrius, MD, Children's Hospital of Pittsburgh, Nephrology Division, Pittsburgh, Pa. (USA)
- Espinol, Carlos Hugo, Professorial Lecturer, Georgetown University School of Medicine, Arlington, Va. (USA)
- Farrant, Pat, DCRMU, Division of Radiology, Clinical Research Centre, Harrow, Middx. (England)
- Flückiger, R., PhD, Diabetologisches Labor, Zentrum für Lehre und Forschung, Kantonsspital Basel, Basel (Switzerland)
- Goudswaard, J., DVM, PhD, Red Cross Bloodbank S.W. Netherlands and Reg. Laboratory of Public Health, Goes (The Netherlands)
- Gozzo, James J., PhD, Northeastern University, Boston, Mass. (USA)
- Grannum, Peter, MD, Yale University School of Medicine, Department of Obstetrics and Gynecology, New Haven, Conn. (USA)
- Harkiss, G.D., PhD, Addenbrooke's Hospital, Cambridge (England)
- Homburger, H.A., MD, Mayo Clinic, Department of Laboratory Medicine, Rochester, Minn. (USA)
- Leithner, C., MD, 2nd Department of Internal Medicine, University of Vienna, Vienna (Austria)
- Leonard, Joe C., MD, Nuclear Medicine Department, Oklahoma Children's Memorial Hospital, Oklahoma City, Okla. (USA)
- Moreau, J.F., MD, Department of Uroradiology, Hôpital Necker, Paris (France)
- Morrin, P.A.F., BSc, MB, BCh, FRCP(C), Division of Nephrology, Department of Medicine, Queen's University, Kingston, Ont. (Canada)
- Nagase, Mitsumasa, MD, First Department of Medicine, School of Medicine, University of Hamamatsu, Hamamatsu-shi, Shizuoka-ken (Japan)
- Pedio, G., MD, Department of Cytology, Institute of Pathology, University of Zürich, Zürich (Switzerland)
- Pfleiderer, Gerhard, Institute for Organic Chemistry, Biochemistry and Isotope Research, University of Stuttgart, Stuttgart (FRG)
- Schnurr, E., MD, Medizinische Klinik A der Universität Düsseldorf, Düsseldorf (FRG)
- Statius van Eps, L.W., MD, Slotervaarthospital, Department of Internal Medicine, Amsterdam (The Netherlands)
- Wieslander, Jörgen, MD, Department of Nephrology, University Hospital, Lund (Sweden)

Contents

Preface.....	XI
List of Contributors.....	XII

Biochemical Diagnosis

P. R. Beck

1 γ -Glutamyltransferase in Kidney Disease.....	2
Introduction.....	2
Methods.....	4
GGT in Renal Disease.....	8
GGT Heterogeneity.....	12
Serum GGT.....	13
Conclusion.....	13
References.....	13

J. Goudswaard and G. Virella

2 Role and Value of Lysozyme Determination for Non-Invasive Diagnosis of Kidney Disease.....	19
Biological Function of Lysozyme.....	19
Lysozyme Estimation: Its Diagnostic Significance.....	20
Estimation of Lysozyme: Methodology.....	21
Other Methods for Quantitative Determination of Lysozyme.....	27
Lysozymuria in the Dog: an Index of Renal Tubular Damage.....	29
Other Tests with Comparable, Diagnostic Significance.....	33
Concluding Remarks.....	34
References.....	36

H. A. Homburger, G. L. Jacob and R. P. Tracy

3 Immunoreactive Creatine Kinase B: Measurement by Radioimmunoassay in Patients with Renal Failure, Renal Allografts or Neoplasia of the Genitourinary Tract.....	38
Material and Methods.....	40
Results.....	43
Discussion.....	49
References.....	50

G. Pfeiderer, E. Mössner, M. Baier and T. Kaufmann

4	Role of Alkaline Phosphatase Isoenzyme Determination in Urine for Non-Invasive Diagnosis of Renal Diseases.....	53
	Methods.....	54
	Results.....	58
	Discussion.....	70
	References.....	72

E. Schnurr

5	Inulin and PAH Clearance in the Steady State without Urine Collection.....	74
	Conditions for the Calculation of the Method.....	75
	Evaluation of the Clearance Method.....	76
	Results.....	77
	Discussion.....	82
	References.....	84

C.H. Espinel

6	Non-Invasive Differential Diagnosis of Acute Renal Failure.....	85
	History.....	86
	Physical Examination.....	90
	Testing Procedures.....	92
	References.....	95

R. Flückiger

7	Assessment of Uremia by Hemoglobin Carbamylation.....	96
	Quantitation of Valine Hydantoin by Gas Chromatography.....	97
	Results and Discussion.....	98
	References.....	102

L.W. Statius van Eps and G.H.C. Schardijn

8	β_2 -Microglobulin and the Renal Tubule.....	103
	Biosynthesis and Release of β_2 -Microglobulin.....	105
	Turnover of β_2 -Microglobulin.....	106
	Renal Handling of β_2 -Microglobulin.....	106
	β_2 -Microglobulin Excretion in Pre- and Postnatal Life.....	107
	Serum Concentration.....	108
	β_2 -Microglobulin in Nephrology.....	109
	Degradation of β_2 -Microglobulin in Urine.....	110
	Tubular Reabsorption Capacity for β_2 -Microglobulin.....	111
	Renal Excretion of β_2 -Microglobulin in Normal Subjects.....	112
	β_2 -Microglobulin Excretion in Renal Disorders.....	113
	Aminoglycosides Nephrotoxicity.....	114
	Balkan Nephropathy.....	115

Fanconi's Syndrome and Other Causes of Tubular Proteinuria	116
Renal Intoxication with Cadmium and Other Metals	116
Gold	119
Cisplatinum	120
β_2 -Microglobulin and Renal Transplantation	120
β_2 -Microglobulin in Obstructed Urinary Pathways	123
β_2 -Microglobulin and Toxemia of Pregnancy	124
β_2 -Microglobulin in Urinary Tract Infections	125
β_2 -Microglobulin and Disturbances in the Renal Circulation	128
β_2 -Microglobulin in Connective Tissue Diseases	131
β_2 -Microglobulin and the Gammopathies	133
Conclusions	134
References	135
<i>P. M. S. Clark</i>	
9 Iso Dalt Analysis of Urinary Proteins	144
Introduction	144
Methodology	148
Applications to the Analysis of Urine Proteins	154
Conclusions	160
Note Added in Proof	160
Acknowledgements	160
References	161
Immunological Diagnosis	
<i>G. D. Harkiss</i>	
10 Clinical Activity, Circulating Immune Complexes, DNA-Antibodies and Complement in Patients with Systemic Lupus Erythematosus	166
Immune Complexes	166
Antibodies to ds DNA	174
Complement	180
Inter-Relationship between CIC, DNA Antibodies, Complement and Disease Activity	182
Conclusions	183
References	184
<i>D. Ellis and I. Stachura</i>	
11 Clinical Application of Urinary Immune Complexes in Glo- merulonephritis	189
Patients and Methods	189
Results	191
Discussion	191
References	201



J. J. Gozzo

12	Immunodiagnosis of Bladder Cancer.....	204
	Methods and Results.....	208
	Discussion.....	213
	References.....	215

M. Nagase and N. Honda

13	Serum Complement as a Guideline to Diagnosis of Renal Diseases.....	218
	Classical Pathway.....	218
	Alternate Pathway.....	220
	Synthesis and Degradation of Complement.....	221
	Complement Measurements.....	221
	Materials.....	224
	Procedure.....	224
	Serum Complement Levels in Renal Diseases.....	225
	References.....	230

J. Wieslander, P. Bygren and D. Heinegård

14	Anti-Glomerular Basement Membrane Antibody Assay of Circulating Antibodies.....	231
	Antigens in Isolated GBM.....	232
	Diagnosis of Anti-GBM Antibody Disease.....	233
	Specificity of Antibodies in Anti-GMB Disease.....	238
	Antibody Class in Anti-GBM Antibody Disease.....	240
	Significance of Circulating Anti-GBM Antibodies.....	240
	Determination of Anti-GBM Antibody Using ELISA.....	242
	Acknowledgements.....	252
	Appendix.....	252
	References.....	253

Cytological Diagnosis

G. Pedio

15	Clinical Application of Urinary Cytology with Special Reference to the Diagnosis of Urinary Tract Neoplasms.....	258
	Material and Methods.....	259
	Cytology of Normal Urine.....	260
	Cytology of Benign Lesions of the Urinary Tract.....	262
	Cytology of Tumors of the Urinary System.....	266
	Cellular Changes Due to Therapy.....	274
	References.....	275

Radiological Diagnosis

<i>H. Carty</i>	
16	Dimercaptosuccinic Acid Imaging of the Kidneys..... 280
	Introduction..... 280
	History..... 280
	Pharmacology and Pharmacokinetics..... 280
	Preparation..... 281
	Injected Dose..... 281
	Radiation Dosimetry..... 281
	Technique..... 282
	Uses in Clinical Practice..... 284
	Assessment of Cortical Mass and Scarring..... 285
	Visualization of 'Difficult-To-See' Kidneys..... 289
	Renal Assessment in Tracheo-Oesophageal Fistula, Ano-Rectal Atresia, Potter's Syndrome..... 291
	Pre-Operative Assessment Prior to Ureteric Reimplantation..... 292
	Space-Occupying Lesions and Renal Mass Lesions..... 292
	Segmental Renal Artery Stenosis..... 293
	Follow-Up..... 293
	Advantages/Disadvantages..... 294
	References..... 296
<i>P. Farrant</i>	
17	Ultrasound Diagnosis of Fetal Urinary Obstructions..... 297
	Case Reports and Literature Review..... 300
	Discussion..... 309
	Conclusion..... 314
	References..... 314
<i>P. Grannum</i>	
18	Assessment of Fetal Kidney Size..... 316
	Method..... 318
	Conclusion..... 321
	References..... 323
<i>J.F. Moreau, B. Ody, C. Rethers and C. Sambourg</i>	
19	Ultrasonographic Investigation of Transplanted Kidneys..... 324
	Technical Procedures..... 324
	Ultrasonographic Anatomy of the Transplanted Kidney..... 327
	Pathological Findings..... 327
	Conclusion..... 332
	References..... 333

P.A.F. Morrin

20	Use of Computerized Axial Tomography Scanning to Evaluate Bleeding after Renal Biopsy.....	334
	Material and Methods.....	335
	Discussion.....	339
	Conclusion.....	342
	References.....	343

J.C. Leonard and E.W. Allen

21	Use of Technetium-99m Sulfur Colloid in the Diagnosis of Transplant Rejection.....	344
	Mechanism.....	344
	Technique.....	345
	Interpretation.....	345
	Clinical Application.....	349
	References.....	351

C. Leithner, H. Sinzinger, M. Schwarz, K. Widhalm, G. Syré and P. Angelberger

22	Use of Autologous Labelled Platelets as a Diagnostic Tool after Kidney Transplantation.....	354
	Material and Methods.....	357
	Results.....	359
	Discussion.....	363
	References.....	365

	Subject Index.....	367
--	--------------------	-----

Biochemical Diagnosis

Peter R. Beck

Introduction

Distribution

γ -Glutamyltransferase (GGT) (EC 2.3.2.2) is a ubiquitous enzyme in nature which has its chief role in clinical medicine in the measurement of serum GGT for the diagnosis of hepatic disease [28, 68, 80]. However, the highest concentration of GGT occurs in the kidney [27], where it is found in the proximal tubular epithelium. Histochemical studies have shown that the GGT is localized to the brush border surface of the epithelial cells [2], and this has been confirmed by ultrastructural histochemistry [75].

Recent studies using isolated membranes have confirmed the close relationship which exists between brush border membranes and the structure and possible functions of GGT [34, 36].

Structure and Generation of Kidney GGT

GGT is a glycoprotein having an apparent molecular size of approximately 90×10^3 daltons [92]. Kidney GGT purified from a variety of species has a subunit structure. The subunits, which differ in size, are designated large and small forms [34]. The estimated size of these fractions vary between species [84, 92] but in the human appear to be of between 51 and 54×10^3 and 27×10^3 daltons respectively [37, 92]. The active site of the enzyme resides on the smaller subunit [33]. Experimental studies suggest that this smaller subunit is oriented on the surface of the brush border membrane in contact with the tubular fluid, whilst the heavy subunit acts as an anchor piece to spatially arrange the GGT in relation to the lipid membrane [34, 36].

Function

The true physiological function of GGT is unknown. The action of GGT is to transfer the glutamyl radical in γ linkage from one peptide

1 γ -Glutamyltransferase in Kidney Disease

Peter R. Beck

Introduction

Distribution

γ -Glutamyltransferase (GGT) (EC 2:3.2.2) is a ubiquitous enzyme in nature which has its chief role in clinical medicine in the measurement of serum GGT for the diagnosis of hepatic disease [28, 68, 80]. However, the highest concentration of GGT occurs in the kidney [27], where it is found in the proximal tubular epithelium. Histochemical studies have shown that the GGT is localized to the brush border surface of the epithelial cells [2], and this has been confirmed by ultra-structural histochemistry [73].

Recent studies using isolated membranes have confirmed the close relationship which occurs between brush border membranes and the structure and possible functions of GGT [34, 36].

Structure and Orientation of Kidney GGT

GGT is a glycoprotein having an apparent molecular size of approximately 90×10^6 daltons [92]. Kidney GGT purified from a variety of species has a subunit structure. The subunits, which differ in size, are designated 'large' and 'small' forms [34]. The estimated size of these fractions vary between species [84, 92] but in the human appear to be of between 51 and 54×10^6 and 27×10^6 daltons, respectively [37, 92]. The active site of the enzyme resides on the smaller subunit [33]. Experimental studies suggest that this smaller subunit is oriented on the surface of the brush border membrane in contact with the tubular fluid, whilst the heavy subunit acts as an anchor piece to spatially arrange the GGT in relation to the lipid membrane [34, 36].

Function

The true physiological function of GGT is unknown. The action of GGT is to transfer the glutamyl radical in γ linkage from one peptide

or amino acid to another peptide or amino acid (transferase activity), or to water (hydrolytic activity) (fig. 1).

The most widespread γ -glutamyl containing peptide is glutathione (GSH), γ -glutamyl-cysteinyl-glycine. A multienzyme cycle has been described, the γ -glutamyl cycle [56], which appears to play an important part in the synthesis and degradation of GSH. GGT is an important constituent enzyme of this cycle, and it has been proposed that the function of GGT is in the mediation of amino acid or peptide transport across the proximal tubular epithelium through the activity of the γ -glutamyl cycle [82]. However, it should be noted that patients with abnormalities of the γ -glutamyl cycle [11, 89], or with tissue deficiencies of GGT do not suffer impairment of amino acid transport [29, 71].

Recently more emphasis has been placed on the possible hydrolytic actions of GGT. Evidence has been provided that in the presence of substrate concentrations which may be found intracellularly or in proximal tubular fluid then a hydrolytic action is much more likely to occur than a transferase action [23, 86]. On this basis it is suggested that the main function of GGT is to control the extracellular breakdown of GSH [19]. These suggestions await confirmation, and the ultimate significance of such a hydrolytic action is unknown.





Fig. 1. Possible transferase and hydrolytic actions of GGT.

Methods

Introduction

There have been a large number of substrates used for the assay of GGT in serum, urine and tissues varying in complexity, stability, and convenience of use [16, 26, 27, 61, 64, 83]. Although experimental studies, especially recently, have concentrated on 'physiological' substrates for GGT [19, 86], most clinical studies have utilized one of a variety of synthetic chromogenic or fluorimetric substrates. Any of the generally available assay methods for serum GGT are equally suitable with little or no modification for the assay of GGT in urine. Differences relate only to preparation of the sample before assay, and this is discussed more fully below after a description of the assay used in the author's own laboratory.

Principle



Automated Kinetic Assay

Reagents

(1) Tris buffer, 0.23 mol/l. Dissolve 27.83 g tris (tris (hydroxymethyl) aminomethane) in approximately 800 ml distilled water. Correct the pH to 8.1 using concentrated hydrochloric acid and make up to 1 litre with distilled water. Store at 4 °C and discard if turbidity develops.

(2) Buffered substrate, 4.57 mmol/l. Weigh 130.4 mg of γ -l-glutamyl-*p*-nitroanilide monohydrate (GLUPA) into a conical flask and add approximately 95 ml of tris buffer. Warm to 60 °C on a magnetic stirrer-hot plate, which should dissolve the substrate, then allow to cool to room temperature. Transfer to a volumetric flask and make up to 100 ml with tris buffer. Store at room temperature, and use within 48 h.

(3) Starting reagent, glycylglycine, 640 mmol/l. Dissolve 4.224 g glycylglycine in approximately 30 ml distilled water, and make up to 50 ml with distilled water. Store at 4 °C. It is stable for 2–3 weeks.

Method

Add 0.1 ml of serum or urine to 1.4 ml of buffered substrate and preincubate to 37 °C for the minimum time possible. Accelerate the reaction with 0.1 ml of glycylglycine and monitor increasing absorbance for 1 min. at 410 nm. Final concentrations in the reaction mixture are GLUPA, 4 mmol/l; glycylglycine 40 mmol/l; tris, 200 mmol/l.

Calculation

Absorbance change per minute (Δ_A) is converted to U/l using the following formula [38]:

$$\text{GGT activity (U/l)} = \Delta_A \times \frac{1,000 \times V_{\text{tot}}}{E \times d \times V_{\text{ser}}}$$

where V_{tot} = total reaction volume (ml), V_{ser} = serum or urine volume (ml), E = millimolar absorptivity of *p*-nitroaniline/cm path length = 8.76 at 410 nm, d = path length (cm).

The assay [9] was originally used on an LKB 8600 Reaction Rate Analyser, measuring at 37°C, but by appropriate adjustment of stock solution concentrations, and the factor for conversion to U/l, the assay may be used on any reaction rate instrument. It has been shown [5, 10] that the activities obtained using this assay are not significantly different from those kits using GLUPA-carboxylate as substrate as marketed for example by BCL (Lewes, Sussex, England).

Manual Assay

The method given below [8] is suitable for use in the absence of automated equipment. This method and the kinetic method described above give results which are not significantly different [5].

Reagents

- (1) Buffered substrate, GLUPA, 114 mg; glycylglycine 660 mg and 2-amino-2-methyl-propan-1,3-diol (Ammediol), 1.8375 g is weighed into a 100-ml volumetric flask and made up to volume with distilled water. Transfer to a beaker and warm to 60°C with constant stirring until dissolved. Allow to cool, adjust the pH to 8.25 with concentrated hydrochloric acid and make the volume up to 100 ml with distilled water. Make up daily.
- (2) Hydrochloric acid, 0.04 mol/l.

Method

Pipette 1 ml of buffered substrate into a test tube (test), and 1 ml of water into a second test tube (serum/urine blank). Allow to stabilize at 37°C in a water-bath and initiate the reaction with 0.1 ml of serum or urine added to both test and blank tubes. Include a reagent blank (1 ml of buffered substrate + 0.1 ml of water) with each batch of assays. Incubate at 37°C for 45 min. and stop the reaction with 5 ml of 0.04 mol/l hydrochloric acid. Read the absorbances in a spectrophotometer at 405 nm. Correct the measured absorbances both for the serum/urine blank absorbance and for the reagent blank absorbance.

Calculation

GGT activity (U/l) =

(absorbance (test) – absorbance (serum/urine blank) – absorbance (substrate blank))

$$\times \frac{1000 \times V_{\text{tot}}}{E \times d \times V_{\text{ser}} \times \text{incubation time}}$$

where V_{tot} = total reaction volume = 6.1 ml, V_{ser} = serum/urine volume = 0.1 ml, E = millimolar absorptivity of *p*-nitroaniline at 405 nm = 8.76, d = path-length of spectrophotometer cell (usually 1 cm), min = incubation time = 45 min.

Sample Handling

Stability

Serum GGT is stable for 24 h at room temperature, at least 1 week at 4°C and for more than 1 year at –20°C [5]. By contrast GGT in urine is not stable when frozen [15, 69, 78] except in some patients with renal failure [8], but should be stored at 4°C prior to assay which should be within 1 week. It appears that urea is a major factor responsible

for the instability of GGT in urine which has been frozen [8]. Stability may be improved either by prior dialysis [8, 78] or by addition of dimethyl-sulphoxide [78] to the urine, but this is unnecessary unless long-term storage is required.

Inhibitors

Szasz [79] originally described the presence of dialyzable inhibitors of GGT in urine. Although this has been confirmed [66], other authors, including the present one [8, 20, 26, 78], have been unable to detect an increase in urinary GGT following dialysis. It is likely that any inhibitors which are present are of no significance in an assay system using less than 10% sample volume [18]. Maruhn et al. [52, 53] have used microcolumn gel permeation chromatography to remove inhibitors of urinary GGT and other enzymes prior to assay.

Centrifugation

Following centrifugation of urine the GGT activity of the supernatant is less than that of well-mixed urine prior to centrifugation [15, 59, 63]. This may be related to the GGT activity of the tubular cells and leucocytes contained in the deposit [79].

Bacterial Contamination

GGT is both produced [4, 57, 81] and destroyed [4] by a variety of bacterial species. Although defined acute bacterial infection of the urinary tract has not been described as a cause of increased urinary GGT activity, bacterial contamination must be considered as a cause of anomalous results. Sodium azide and thiomersalate do not affect GGT activity and may be used as preservative [4].

Temporal Variation

Diurnal Variation

40 normal individuals collected urine over a 24-hour period divided into the following time periods: 0800–1300, 1300–1800, 1800–2300, 2300–0800. The GGT activity was measured for each time period and the results expressed as U/5-hour period. The results are indicated in fig. 2. There was a significantly greater excretion rate during the period 0800–1300. There was no difference between sexes. A similar variation was found by Cho et al. [17].

Day-to-Day Variation

Studies on small numbers of individuals [4] suggests that the day-to-day variation in GGT excretion (U/24 h) is normally no more than 5–10 U.

Sex Variation

Whilst some authors have found no differences between males and females [44, 84], others have found males to excrete more GGT than females [50, 51, 79].

Expression of GGT Excretion

A variety of methods have been used for expressing the results of urinary GGT excretion, including as a concentration (U/l) [35, 61]; as an excretion rate, e.g. U/3 h [51], U/8 h [50], U/24 h [85, 91]; as a ratio to creatinine excretion [51, 59, 67]; or as a ratio to creatinine clearance [6, 7, 84]. The basis for relating GGT excretion to creatinine excre-